Market Response: Cannabis Stocks Rally

Following Trump’s post, cannabis stocks soared when markets opened Monday:

• • Tilray shares surged more than 40% in a single day.

• • Canopy Growth and Cronos Group also saw significant gains.

• • The MSOS ETF, which tracks U.S. cannabis companies, spiked as well.

This dramatic market reaction underscores just how much influence federal policy—and even hints of policy shifts—carry in the cannabis space.

---

The Bigger Picture: Rescheduling & Federal Reform

While Trump has historically been quiet on cannabis reform, his recent comments signal a potential shift. At a fundraiser in August, he said he was “looking at reclassification” of marijuana and may consider moving it to Schedule III, a classification that acknowledges medical use and reduces barriers to research.

For context:

• • Cannabis remains a Schedule I drug under federal law, grouped with heroin and LSD.

• • This classification restricts research and prevents integration into mainstream healthcare.

• • Meanwhile, 40 states have legalized medical cannabis, and 24 states permit adult-use.

The Biden administration has also pressured the DEA to review cannabis scheduling, following a recommendation from the Department of Health and Human Services. But no final decision has been made.

---

Why Seniors Are Turning to Cannabis

According to recent studies, seniors are the fastest-growing demographic of cannabis consumers in the U.S. Many older adults are seeking alternatives to prescription medications for:

• • Chronic pain

• • Insomnia and sleep disturbances

• • Anxiety and stress

• • Inflammation and mobility challenges

As Dr. Alison Moore, a geriatrician and professor at UC San Diego, explains: “We do know people find it useful.” Despite limited clinical research due to federal restrictions, anecdotal reports and early studies continue to build momentum.

---

What’s Next?

Whether Trump’s remarks translate into meaningful policy change remains uncertain. His DEA administrator, Terrance Cole, has not prioritized cannabis rescheduling publicly, focusing instead on combating fentanyl. Still, advocates are optimistic that renewed federal discussion—paired with undeniable market demand—could open doors for broader acceptance and access.

For the cannabis industry, one thing is clear: federal leadership on hemp and cannabis policy directly impacts consumer access, research funding, and market stability.

---

Final Thoughts from RESTART CBD + THC

At RESTART, we’ve always believed in the power of hemp-derived cannabinoids like CBD to support wellness naturally. As the conversation reaches the highest levels of government, we remain committed to educating our community, advocating for sensible cannabis policy, and providing safe, high-quality products that consumers can trust.

This latest development is a reminder of just how rapidly the cannabis landscape can shift—and why staying informed matters.

Shop some of our best sellers below